[Comparison of mortality and morbidity in newborns treated with ambroxol prenatally and postnatally].
The effect of Ambroksol given pre- and postnatal on infant mortality and morbidity was performed. In particular we found a statistically significant differences in reduction of mortality in the group A treated with Ambroksol pre- and postnatal vs. group B treated only postnatal. The other parameters of morbidity had no significantly importance but sepsis, which was more often diagnosed in group A than in group B (17.5% vs. 11.1%). We connect this fact with higher frequency of PROM in the group A.
Sackey
S
S
Kliniki Neonatologii Instytutu Ginekologii i Połoznictwa AM w Poznaniu.
Gadzinowski
J
J
Szymankiewicz
M
M
Breborowicz
G H
GH
Rudnicki
J
J
Patalan
J
J
Rózewicki
K
K
D000551:Ambroxol / Q000627:therapeutic use*; D001034:Apgar Score; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D007231:Infant, Newborn; D007235:Infant, Premature, Diseases / Q000188:drug therapy* / Q000453:epidemiology*; D011181:Postnatal Care; D011247:Pregnancy; D011295:Prenatal Care; D015996:Survival Rate
D000551:Ambroxol
Porównanie śmiertelności i zachorowalności noworodków leczonych Ambroksolem prenatalnie i pourodzeniowo.